Protecting Patients from Deceptive Drug Ads Online Act
Latest Action
Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text: CR S6021-6022)
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The Protecting Patients from Deceptive Drug Ads Online Act (Senate Bill 5040, 118th Congress) is a legislative proposal introduced in the Senate aimed at addressing concerns related to deceptive advertising of pharmaceutical drugs on online platforms. The bill was read twice and referred to the Senate Committee on Health, Education, Labor, and Pensions on September 12, 2024. However, the bill did not advance further and is currently classified as failed or expired. No official summary or full text of the bill is publicly available, limiting detailed analysis of its provisions or mechanisms.
This bill sought to regulate deceptive online drug advertisements but did not progress beyond committee referral and has since expired without enactment.
- The bill focuses on the health policy area, specifically targeting deceptive drug advertisements online.
- It was introduced in the Senate during the 118th Congress and referred to the Committee on Health, Education, Labor, and Pensions.
- No official summary or full text is available, and the bill ultimately failed or expired without further legislative action.
['Patients and consumers seeking accurate information about pharmaceutical drugs online.', 'Regulatory agencies responsible for overseeing drug advertising and consumer protection.', 'Healthcare providers who rely on truthful drug information for patient care.']
['Lack of publicly available full bill text limits understanding of enforcement mechanisms and regulatory scope.', "Potential challenges in defining and identifying 'deceptive' advertising in an online context.", 'Implementation costs and responsibilities for monitoring online platforms are unclear.', 'Oversight authority and coordination among federal agencies are not specified due to missing text.']
The bill was introduced during the 118th Congress and referred to the Senate Committee on Health, Education, Labor, and Pensions but did not advance beyond this stage. Its failure or expiration indicates it did not receive sufficient legislative support or prioritization to move forward. The absence of an official summary or full text in public records suggests limited transparency or dissemination of the bill's detailed provisions.
Hidden impact flags detected: 2
GovScope reviewed 2 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['Potential increased scrutiny of online pharmaceutical advertising if similar legislation is introduced in the future.', 'Possible influence on online platforms to self-regulate drug advertisements to avoid future regulatory action.', 'Heightened awareness among consumers about the risks of deceptive drug ads online.']
The absence of an official summary and full bill text restricts comprehensive analysis and public understanding of the bill's scope, enforcement, and impact. Transparency in legislative documentation is critical for informed public discourse and effective oversight. The bill's failure to advance highlights the importance of accessible legislative information for tracking policy developments.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.